Skip to main content

GlaxoSmithKline strikes $300 million deal with 23andMe for genetics-driven drug research

The partnership is for four years but has an option to extend for an additional year. Funding and proceeds will be split equally.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.